Skip to content

bronchovascular structures analysis of the home lobe for non-small cell lung cancer in the incomplete interlobar fissures

bronchovascular structures analysis of the home lobe for non-small cell lung cancer in the incomplete interlobar fissures:a single-center, prospective, open-label, single-arm phase 3 clinical study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092443
Enrollment
Unknown
Registered
2024-11-15
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

Surgical resection group:Lobectomy+ Sublobar resection

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age: >= 18 years old; sex-neutral, resectable NSCLC; 2. Solid nodules in the incomplete pulmonary fissure area, and the preoperative puncture confirmed NSCLC; 3. No history of ipsilateral thoracotomy, and no previous chemotherapy or radiotherapy for any malignant disease; 4. Normal function of major organs; (1) Routine blood examination: a.HB>=90g/L; b.ANC>=1.5x10^9/L; c.PLT>=80x10^9/L; (2) Biochemical examination: a. ALB > = 30 g/L: b. ALT and AST = 60 ml/min: 5. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) >= low limit of normal (50%); 6. Physical fitness score (ECOG) of 0, 1, or 2; 7. Subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with follow-up

Exclusion criteria

Exclusion criteria: 1.active bacterial or fungous infection; 2.women during pregnancyor breast-feeding; 3.simultaneous or metachronous double cancers within the past 5 years; 4.Patients with a history of psychotropic drug abuse and inability to abstain or with mental disorders; 5.Uncontrolled diabetes or high blood pressure; 6.interstitial pneumonitis,pulmonary fibrosis,or severe pulmonary emphysema; 7.history of severe heart disease, heart failure, myocardial infarction within the past 6 months or attack of angina pectoris within the past 6 months. 8. According to the judgment of the investigator, patients with concomitant diseases (such as acute myocardial infarction, cerebral infarction, pulmonary embolism, etc.) that seriously endanger the safety of patients or affect the completion of the study 9.Patients considered unsuitable for this study by the investigators.

Design outcomes

Primary

MeasureTime frame
Overall Survival(OS);

Secondary

MeasureTime frame
Disease Free Survival;post-operative respiratory function;

Countries

China

Contacts

Public ContactXiangnan Li

The First Affiliated Hospital of Zhengzhou University

lxn-2000@163.com+86 135 9250 2553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026